202 related articles for article (PubMed ID: 29608486)
1. Simultaneous Quantification of Adalimumab and Infliximab in Human Plasma by Liquid Chromatography-Tandem Mass Spectrometry.
Jourdil JF; Némoz B; Gautier-Veyret E; Romero C; Stanke-Labesque F
Ther Drug Monit; 2018 Aug; 40(4):417-424. PubMed ID: 29608486
[TBL] [Abstract][Full Text] [Related]
2. Infliximab quantitation in human plasma by liquid chromatography-tandem mass spectrometry: towards a standardization of the methods?
Jourdil JF; Lebert D; Gautier-Veyret E; Lemaitre F; Bonaz B; Picard G; Tonini J; Stanke-Labesque F
Anal Bioanal Chem; 2017 Feb; 409(5):1195-1205. PubMed ID: 27826630
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous Quantification of Free Adalimumab and Infliximab in Human Plasma Using a Target-Based Sample Purification and Liquid Chromatography-Tandem Mass Spectrometry.
El Amrani M; Bosman SM; Egas AC; Hack CE; Huitema ADR; van Maarseveen EM
Ther Drug Monit; 2019 Oct; 41(5):640-647. PubMed ID: 31584927
[TBL] [Abstract][Full Text] [Related]
4. Quantification of active infliximab in human serum with liquid chromatography-tandem mass spectrometry using a tumor necrosis factor alpha -based pre-analytical sample purification and a stable isotopic labeled infliximab bio-similar as internal standard: A target-based, sensitive and cost-effective method.
El Amrani M; van den Broek MP; Göbel C; van Maarseveen EM
J Chromatogr A; 2016 Jul; 1454():42-8. PubMed ID: 27264745
[TBL] [Abstract][Full Text] [Related]
5. A multiplex liquid chromatography tandem mass spectrometry method for the quantification of seven therapeutic monoclonal antibodies: Application for adalimumab therapeutic drug monitoring in patients with Crohn's disease.
Willeman T; Jourdil JF; Gautier-Veyret E; Bonaz B; Stanke-Labesque F
Anal Chim Acta; 2019 Aug; 1067():63-70. PubMed ID: 31047150
[TBL] [Abstract][Full Text] [Related]
6. Verification between Original and Biosimilar Therapeutic Antibody Infliximab Using nSMOL Coupled LC-MS Bioanalysis in Human Serum.
Iwamoto N; Yokoyama K; Takanashi M; Yonezawa A; Matsubara K; Shimada T
Curr Pharm Biotechnol; 2018; 19(6):495-505. PubMed ID: 29968534
[TBL] [Abstract][Full Text] [Related]
7. Agreement in assessment of infliximab and adalimumab levels in rheumatoid arthritis: interlaboratory and interassay comparison.
Valor L; Hernández-Flórez D; de la Torre I; Llinares F; Rosas J; Yagüe J; Garrido J; Naredo E
Clin Exp Rheumatol; 2015; 33(5):617-23. PubMed ID: 26316061
[TBL] [Abstract][Full Text] [Related]
8. Infliximab and adalimumab concentrations and anti-drug antibodies in inflammatory bowel disease control using New Zealand assays.
Barclay ML; Karim S; Helms ETJ; Keating PE; Hock B; Stamp LK; Schultz M
Intern Med J; 2019 Apr; 49(4):513-518. PubMed ID: 30091273
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous quantification of rituximab and eculizumab in human plasma by liquid chromatography-tandem mass spectrometry and comparison with rituximab ELISA kits.
Truffot A; Jourdil JF; Seitz-Polski B; Malvezzi P; Brglez V; Stanke-Labesque F; Gautier-Veyret E
Clin Biochem; 2021 Jan; 87():60-66. PubMed ID: 33096054
[TBL] [Abstract][Full Text] [Related]
10. Quantification of infliximab and adalimumab in human plasma by a liquid chromatography tandem mass spectrometry kit and comparison with two ELISA methods.
Tron C; Lemaitre F; Bros P; Goulvestre C; Franck B; Mouton N; Bagnos S; Coriat R; Khoudour N; Lebert D; Blanchet B
Bioanalysis; 2022 Jun; 14(11):831-844. PubMed ID: 35735172
[No Abstract] [Full Text] [Related]
11. Routinely utilized in-house assays for infliximab, adalimumab and their anti-drug antibody levels.
Ogrič M; Žigon P; Drobne D; Štabuc B; Sodin-Semrl S; Čučnik S; Praprotnik S
Immunol Res; 2018 Dec; 66(6):726-736. PubMed ID: 30569379
[TBL] [Abstract][Full Text] [Related]
12. Optimization of a Quantitative Anti-Drug Antibodies against Infliximab Assay with the Liquid Chromatography-Tandem Mass Spectrometry: A Method Validation Study and Future Perspectives.
Smeijsters EH; van der Elst KCM; Visch A; Göbel C; Loeff FC; Rispens T; Huitema ADR; van Luin M; El Amrani M
Pharmaceutics; 2023 May; 15(5):. PubMed ID: 37242719
[TBL] [Abstract][Full Text] [Related]
13. A retrospective comparison of infliximab versus adalimumab as induction and maintenance therapy for Crohn disease.
Varma P; Paul E; Huang C; Headon B; Sparrow MP
Intern Med J; 2016 Jul; 46(7):798-804. PubMed ID: 26865349
[TBL] [Abstract][Full Text] [Related]
14. Development of Label-Free Immunoassays as Novel Solutions for the Measurement of Monoclonal Antibody Drugs and Antidrug Antibodies.
Luo YR; Chakraborty I; Lazar-Molnar E; Wu AHB; Lynch KL
Clin Chem; 2020 Oct; 66(10):1319-1328. PubMed ID: 32918468
[TBL] [Abstract][Full Text] [Related]
15. Surface plasmon resonance assays for the therapeutic drug monitoring of infliximab indicate clinical relevance of anti-infliximab antibody binding properties.
Grasmeier MK; Weber S; Treiber M; Thaler MA; Luppa PB
Clin Chem Lab Med; 2023 Jun; 61(7):1255-1265. PubMed ID: 36753693
[TBL] [Abstract][Full Text] [Related]
16. A Genetic Variation in the Neonatal Fc-Receptor Affects Anti-TNF Drug Concentrations in Inflammatory Bowel Disease.
Billiet T; Dreesen E; Cleynen I; Wollants WJ; Ferrante M; Van Assche G; Gils A; Vermeire S
Am J Gastroenterol; 2016 Oct; 111(10):1438-1445. PubMed ID: 27481307
[TBL] [Abstract][Full Text] [Related]
17. Comparison of a new rapid method for determination of serum anti-adalimumab and anti-infliximab antibodies with two established ELISA kits.
Laserna-Mendieta EJ; Salvador-Martín S; Marín-Jiménez I; Menchén LA; López-Cauce B; López-Fernández LA; Lucendo AJ
J Pharm Biomed Anal; 2021 May; 198():114003. PubMed ID: 33714800
[TBL] [Abstract][Full Text] [Related]
18. The efficacy and safety of either infliximab or adalimumab in 362 patients with anti-TNF-α naïve Crohn's disease.
Narula N; Kainz S; Petritsch W; Haas T; Feichtenschlager T; Novacek G; Eser A; Vogelsang H; Reinisch W; Papay P
Aliment Pharmacol Ther; 2016 Jul; 44(2):170-80. PubMed ID: 27226407
[TBL] [Abstract][Full Text] [Related]
19. Generation of a Highly Specific Monoclonal Anti-Infliximab Antibody for Harmonization of TNF-Coated Infliximab Assays.
Van Stappen T; Brouwers E; Tops S; Geukens N; Vermeire S; Declerck PJ; Gils A
Ther Drug Monit; 2015 Aug; 37(4):479-85. PubMed ID: 25525757
[TBL] [Abstract][Full Text] [Related]
20. Anti-TNF Levels in Cord Blood at Birth are Associated with Anti-TNF Type.
Kanis SL; de Lima-Karagiannis A; van der Ent C; Rizopoulos D; van der Woude CJ
J Crohns Colitis; 2018 Jul; 12(8):939-947. PubMed ID: 29771301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]